Objective: To investigate the correlation of serum ADAMTS-1 and ADAMTS-13 contents with plaque nature, inflammatory factors and adipocytokines in patients with coronary heart disease. Methods: A total of 106 patients ...Objective: To investigate the correlation of serum ADAMTS-1 and ADAMTS-13 contents with plaque nature, inflammatory factors and adipocytokines in patients with coronary heart disease. Methods: A total of 106 patients with coronary heart disease undergoing examination in the hospital between September 2014 and June 2017 were enrolled in coronary heart disease group, and 100 healthy volunteers were enrolled in normal control group. Differences in serum ADAMTS-1, ADAMTS-13, plaque nature-related index, inflammatory factor and adipocytokine contents were compared between the two groups. Pearson test was used to assess the correlation of ADAMTS-1 and ADAMTS-13 contents with plaque nature, inflammatory factor and adipocytokines in patients with coronary heart disease. Results: Serum ADAMTS-1 content of coronary heart disease group was higher than that of normal control group whereas ADAMTS-13 content was lower than that of normal control group;serum plaque nature-related indexes Hcy and UA contents were higher than those of normal control group;serum inflammatory factors HMGB1, IL-6, IL-8 and IL-18 contents were higher than those of normal control group;serum adipocytokines APN and Vaspin contents were lower than those of normal control group whereas Visfatin and RBP4 contents were higher than those of normal control group. Pearson test showed that serum ADAMTS-1 and ADAMTS-13 contents of patients with coronary heart disease were directly correlated with the contents of plaque nature-related indexes, inflammatory factors and adipocytokines. Conclusion: Serum ADAMTS-1 content abnormally increases and ADAMTS-13 content abnormally decreases in patients with coronary heart disease, and the specific contents are directly correlated with the condition of coronary heart disease.展开更多
Thrombotic thrombocytopenic purpura(TTP) is a multisystem disorder that essentially can affect any organ in the human body. The hallmark of the pathogenesis in TTP is the large von Willebrand factor multimers on plate...Thrombotic thrombocytopenic purpura(TTP) is a multisystem disorder that essentially can affect any organ in the human body. The hallmark of the pathogenesis in TTP is the large von Willebrand factor multimers on plateletmediated micro-thrombi formation, leading to microvascular thrombosis.Autopsy studies showed that cardiac arrest and myocardial infarction are the most common immediate causes of death in these patients. Clinical manifestations of cardiac involvement in TTP vary dramatically, from asymptomatic elevation of cardiac biomarkers, to heart failure, MI and sudden cardiac death. There is limited knowledge about optimal cardiac evaluation and management in patients with TTP. The absence of typical cardiac symptoms,combined with complicated multi-organ involvement in TTP, may contribute to the under-utilization of cardiac evaluation and treatment. Prompt diagnosis and timely initiation of effective therapy could be critically important in selected cases. Based on our experience and this review of the literature, we developed several recommendations for focused cardiac evaluation for patients with acute TTP:(1) patients with suspected or confirmed TTP should be screened for the potential presence of cardiac involvement with detailed history and physical,electrocardiogram and cardiac enzymes;(2) clinical deterioration of TTP patients warrants immediate cardiac reevaluation;(3) TTP patients with clinical evidence of cardiac involvement should be monitored for telemetry, cardiac biomarkers and evaluated with transthoracic echocardiography. These patients require urgent targeted TTP treatment as well as cardiac-specific treatment. Aspirin therapy is indicated for all TTP patients. Since epicardial coronary artery involvement is rare, cardiac catheterization is usually not required, given the high risk for hemorrhage and kidney injury;(4) we recommend evidence-based medical therapy for ischemic symptoms and heart failure. TTP patients with evidence of cardiac involvement would also benefit from routine cardiology follow up during remission.展开更多
文摘Objective: To investigate the correlation of serum ADAMTS-1 and ADAMTS-13 contents with plaque nature, inflammatory factors and adipocytokines in patients with coronary heart disease. Methods: A total of 106 patients with coronary heart disease undergoing examination in the hospital between September 2014 and June 2017 were enrolled in coronary heart disease group, and 100 healthy volunteers were enrolled in normal control group. Differences in serum ADAMTS-1, ADAMTS-13, plaque nature-related index, inflammatory factor and adipocytokine contents were compared between the two groups. Pearson test was used to assess the correlation of ADAMTS-1 and ADAMTS-13 contents with plaque nature, inflammatory factor and adipocytokines in patients with coronary heart disease. Results: Serum ADAMTS-1 content of coronary heart disease group was higher than that of normal control group whereas ADAMTS-13 content was lower than that of normal control group;serum plaque nature-related indexes Hcy and UA contents were higher than those of normal control group;serum inflammatory factors HMGB1, IL-6, IL-8 and IL-18 contents were higher than those of normal control group;serum adipocytokines APN and Vaspin contents were lower than those of normal control group whereas Visfatin and RBP4 contents were higher than those of normal control group. Pearson test showed that serum ADAMTS-1 and ADAMTS-13 contents of patients with coronary heart disease were directly correlated with the contents of plaque nature-related indexes, inflammatory factors and adipocytokines. Conclusion: Serum ADAMTS-1 content abnormally increases and ADAMTS-13 content abnormally decreases in patients with coronary heart disease, and the specific contents are directly correlated with the condition of coronary heart disease.
文摘Thrombotic thrombocytopenic purpura(TTP) is a multisystem disorder that essentially can affect any organ in the human body. The hallmark of the pathogenesis in TTP is the large von Willebrand factor multimers on plateletmediated micro-thrombi formation, leading to microvascular thrombosis.Autopsy studies showed that cardiac arrest and myocardial infarction are the most common immediate causes of death in these patients. Clinical manifestations of cardiac involvement in TTP vary dramatically, from asymptomatic elevation of cardiac biomarkers, to heart failure, MI and sudden cardiac death. There is limited knowledge about optimal cardiac evaluation and management in patients with TTP. The absence of typical cardiac symptoms,combined with complicated multi-organ involvement in TTP, may contribute to the under-utilization of cardiac evaluation and treatment. Prompt diagnosis and timely initiation of effective therapy could be critically important in selected cases. Based on our experience and this review of the literature, we developed several recommendations for focused cardiac evaluation for patients with acute TTP:(1) patients with suspected or confirmed TTP should be screened for the potential presence of cardiac involvement with detailed history and physical,electrocardiogram and cardiac enzymes;(2) clinical deterioration of TTP patients warrants immediate cardiac reevaluation;(3) TTP patients with clinical evidence of cardiac involvement should be monitored for telemetry, cardiac biomarkers and evaluated with transthoracic echocardiography. These patients require urgent targeted TTP treatment as well as cardiac-specific treatment. Aspirin therapy is indicated for all TTP patients. Since epicardial coronary artery involvement is rare, cardiac catheterization is usually not required, given the high risk for hemorrhage and kidney injury;(4) we recommend evidence-based medical therapy for ischemic symptoms and heart failure. TTP patients with evidence of cardiac involvement would also benefit from routine cardiology follow up during remission.
